NEW YORK, NY / ACCESSWIRE / September 19, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Dingdong (Cayman) Ltd. (NYSE:DDL)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/dingdong-cayman-ltd-loss-submission-form?prid=31921&wire=1
Lead Plaintiff Deadline: October 24, 2022
This lawsuit is on behalf of persons who purchased, or otherwise acquired, Dingdong American Depository Shares pursuant or traceable to the F-1 registration statements and related prospectus on Form 424B4 issued in connection with Dingdong's June 2021 initial public stock offering.
According to the filed complaint, the registration statement and prospectus used to effectuate the Company's initial public offering misstated and/or omitted facts concerning Dingdong's so-called commitment to ensuring the safety and quality of the food it distributes to the market. For example, despite claiming that it applies 'stringent quality control across [its] entire supply chain to ensure product quality to [its] users,' Dingdong sold food past its sell-by date. Consequently, Dingdong was, in fact, no better at providing or assuring access to 'fresh' groceries than the supermarkets, traditional Chinese wet markets, or traditional e-commerce platforms it repeatedly claimed to be displacing. Moreover, the foregoing conduct subjected Dingdong to an increased risk of regulatory and/or governmental scrutiny and enforcement, all of which, once revealed, were likely to negatively impact Dingdong's business, operations, and reputation.
Humanigen, Inc. (NASDAQ:HGEN)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/humanigen-class-action-loss-submission-form?prid=31921&wire=1
Lead Plaintiff Deadline: October 25, 2022
Class Period: May 28, 2021 - July 12, 2022
Allegations against HGEN include that: (i) Humanigen's lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Latch, Inc. f/k/a TS Innovation Acquisitions Corp. (NASDAQ:LTCH)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/latch-inc-loss-submission-form?prid=31921&wire=1
Lead Plaintiff Deadline: October 31, 2022
Class Period: May 13, 2021 - August 25, 2022
Allegations against LTCH include that: (1) there were unreported sales arrangements related to hardware devices; (2) as a result, the Company had improperly recognized revenue throughout fiscal 2021 and first quarter 2022; (3) there were material weaknesses in Latch's internal control over financial reporting related to revenue recognition; (4) as a result of the foregoing, Latch would restate financial statements for fiscal 2021 and first quarter 2022; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: